Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Miya Flora EX
- Development stage
- Unknown
- Lead developer
- Miyarisan Pharmaceutical
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral
01
Overview
Miya Flora EX (ミヤフローラEX) is an over-the-counter gastrointestinal combination product developed and marketed by Miyarisan Pharmaceutical. Classified as a designated quasi-drug in Japan, it is indicated for regulating intestinal function, relieving abdominal bloating, constipation, loose stools, and promoting digestion. The formulation combines two active ingredients: Clostridium butyricum Miyairi (a probiotic butyric acid-producing bacterium) and ursodeoxycholic acid (a bile acid). Clostridium butyricum Miyairi survives gastric acid to reach the large intestine, where it produces short-chain fatty acids (such as butyric acid and acetic acid) to foster beneficial gut microbiota and suppress harmful pathogens. Ursodeoxycholic acid acts as a choleretic agent, stimulating bile and pancreatic secretions to facilitate the digestion and absorption of dietary fats, while also modulating bile acid-activated receptors such as GPBAR1 (TGR5) and FXR.
- Brand names
- Miya Flora EXMiyaflora EXミヤフローラEX
- Other names
- clostridium butyricum + ursodeoxycholic acid
02
Targets
FXR (Farnesoid x-activated receptor)GPBAR1
Beyond the preview
Go deeper on Miya Flora EX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Miya Flora EX.